Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Avilar, we are moving beyond the boundaries of the cell to pioneer the discovery and development of extracellular protein degraders. Our ATACs (ASGPR Targeting Chimeras) are a new class of protein degrader therapeutics that shuttle disease-causing proteins from the circulation to the endolysosome where they are degraded.

List your booth number for exhibitions, ask us